Skip to main content
. Author manuscript; available in PMC: 2011 Apr 14.
Published in final edited form as: Clin Cancer Res. 2009 Jul 7;15(14):4581–4588. doi: 10.1158/1078-0432.CCR-08-2685

Fig. 2.

Fig. 2

In vivo tumor treatment experiments withTC-1tumors. A, diagrammatic representation of the prime-boost treatment regimen. Groups of C57BL/6 mice (five per group) were s.c. challenged with 5 × 104/mouse ofTC-1tumor cells. Five days after tumor challenge, mice were immunized with either 2 μg/mouse of pcDNA3 DNA or pcDNA3-expressing ovalbumin (p-OVA) by gene gun. On day12, mice were boosted by i.t. injection of 1 ×107 pfu/mouse of either wild-type vaccinia (Vac-WT) or vaccinia encoding ovalbumin (Vac-OVA). TC-1tumor-bearing mice treated with 1×PBS were used as a control. B, line graph depicting the tumor volume inTC-1tumor-bearing mice treated with the different prime-boost regimens. Numbers in parentheses indicate complete tumor rejection rates. C, Kaplan-Meier survival analysis ofTC-1tumor-bearing mice treated with the different treatment regimens. Data shown are representative of two experiments. Points, mean; bars, SD.

HHS Vulnerability Disclosure